[go: up one dir, main page]

TNSN99173A1 - Livraison d'agent actif sous forme de poudre seche - Google Patents

Livraison d'agent actif sous forme de poudre seche

Info

Publication number
TNSN99173A1
TNSN99173A1 TNTNSN99173A TNSN99173A TNSN99173A1 TN SN99173 A1 TNSN99173 A1 TN SN99173A1 TN TNSN99173 A TNTNSN99173 A TN TNSN99173A TN SN99173 A TNSN99173 A TN SN99173A TN SN99173 A1 TNSN99173 A1 TN SN99173A1
Authority
TN
Tunisia
Prior art keywords
active agent
dry powder
delivery
lung
hygroscopic
Prior art date
Application number
TNTNSN99173A
Other languages
English (en)
Inventor
Clark Andrew
Kuo Mai-Chang
Lalor Cecily
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of TNSN99173A1 publication Critical patent/TNSN99173A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

=J167-LA PRESENTE INVENTION PORTE SUR DES COMPOSITIONS SOUS FORME DE PARTICULES ET SUR DES METHODES D'ADMINISTRATION D'UN AGENT ACTIF DANS LE POUMON D'UN PATIENT HUMAIN. LA FORMULATION D'AGENT ACTIF EST SOUS FORME D'UNE POUDRE SECHE ET MONTRE (i) UNE FAIBLE ABSORPTION D'HUMIDITE, ET (ii) UNE RESISTANCE AU DEVELOPPEMENT HYGROSCOPIQUE, SURTOUT SOUS DES CONDITIONS SIMULEES DU POUMON. I172
TNTNSN99173A 1998-09-14 1999-09-14 Livraison d'agent actif sous forme de poudre seche TNSN99173A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
TNSN99173A1 true TNSN99173A1 (fr) 2005-11-10

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99173A TNSN99173A1 (fr) 1998-09-14 1999-09-14 Livraison d'agent actif sous forme de poudre seche

Country Status (44)

Country Link
EP (1) EP1117442A1 (fr)
JP (1) JP2002524535A (fr)
KR (1) KR20010075063A (fr)
CN (1) CN1317977A (fr)
AP (1) AP1374A (fr)
AR (1) AR022090A1 (fr)
AU (1) AU753014B2 (fr)
BG (1) BG105430A (fr)
BR (1) BR9913722A (fr)
CA (1) CA2343920A1 (fr)
CO (1) CO5130023A1 (fr)
CZ (1) CZ2001829A3 (fr)
DZ (1) DZ2892A1 (fr)
EA (1) EA003476B1 (fr)
EE (1) EE200100151A (fr)
GE (1) GEP20043257B (fr)
GT (1) GT199900156A (fr)
HK (1) HK1042231A1 (fr)
HN (1) HN1999000159A (fr)
HR (1) HRP20010189A2 (fr)
HU (1) HUP0103837A3 (fr)
ID (1) ID28845A (fr)
IL (2) IL141562A0 (fr)
IS (1) IS5878A (fr)
LT (1) LT4897B (fr)
LV (1) LV12658B (fr)
MA (1) MA25590A1 (fr)
MY (1) MY129282A (fr)
NO (1) NO20011251L (fr)
NZ (1) NZ510168A (fr)
OA (1) OA11781A (fr)
PA (1) PA8481901A1 (fr)
PE (1) PE20001061A1 (fr)
PL (1) PL195574B1 (fr)
SA (1) SA99200718B1 (fr)
SK (1) SK3442001A3 (fr)
TN (1) TNSN99173A1 (fr)
TR (1) TR200101182T2 (fr)
TW (1) TWI226248B (fr)
UA (1) UA76085C2 (fr)
UY (1) UY25711A1 (fr)
WO (1) WO2000015262A1 (fr)
YU (1) YU24201A (fr)
ZA (1) ZA200101995B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
ATE555773T1 (de) 1999-06-09 2012-05-15 Sievers Robert E Überkritische fluidgestützte verneblung und blasen trochnen
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
CA2446904A1 (fr) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
ES2415654T3 (es) 2001-11-20 2013-07-26 Civitas Therapeutics, Inc. Composiciones particuladas mejoradas para suministro pulmonar
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
PL373780A1 (en) 2002-02-25 2005-09-19 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP1539246A4 (fr) * 2002-07-03 2007-05-16 Brigham & Womens Hospital Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques
JP2006513238A (ja) * 2002-12-19 2006-04-20 ファルマシア・コーポレーション 吸湿性薬物を含む非‐吸湿性製剤
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
PT3520779T (pt) 2004-04-23 2022-03-22 Cydex Pharmaceuticals Inc Formulação de dpi contendo éter sulfoalquílicociclodextrina
CN104840455A (zh) * 2005-02-24 2015-08-19 扩散药品有限公司 反式类胡萝卜素、其合成、制剂和用途
BRPI0608844A2 (pt) * 2005-03-09 2010-02-02 Ono Pharmaceutical Co partìcula e preparação que contém a partìcula
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP2952197B1 (fr) 2005-10-26 2017-04-26 CyDex Pharmaceuticals, Inc. Compositions de cyclodextrine d'éther de sulfoalkyle et leurs procédés de préparation
WO2008021451A2 (fr) * 2006-08-14 2008-02-21 Aktiv-Dry Llc Inhalateur à poudre sèche actionné par l'homme et compositions à inhaler sous forme de poudre sèche
US20100093875A1 (en) * 2006-10-25 2010-04-15 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
EP1925295A1 (fr) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Formule de poudre stable contenant un nouveau anticholinergique
BRPI0810647A2 (pt) 2007-04-13 2014-11-04 Diffusion Pharmaceuticals Llc " uso de trans carotenóides bipolares como um pré-tratamento e no tratamento de doença vascular periférica ".
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
EA201070544A1 (ru) 2007-10-31 2010-12-30 Диффьюжн Фармасьютикалз Ллс Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
EP2432502B1 (fr) 2009-05-20 2018-01-03 Aeras Compositions virales immunogènes stables séchées par atomisation
KR101875843B1 (ko) 2009-06-22 2018-07-06 디퓨젼 파마슈티컬즈 엘엘씨 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
CA2866230C (fr) 2012-05-03 2020-08-18 Janssen R&D Ireland Formulations d'acide polyinosinique-polycytidylique (poly (i:c)) pour le traitement d'infections du tractus respiratoire superieur
WO2014074797A1 (fr) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Poudres pulmonaires de densité ultra basse
US20180043585A9 (en) * 2013-09-20 2018-02-15 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
EP3432929A4 (fr) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC Utilisation de caroténoïdes trans bipolaires avec une chimiothérapie et une radiothérapie en vue du traitement d'un cancer
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
CA2115065C (fr) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Poudre particulaire ultrafine pour inhalation et methode de production
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP0954282B1 (fr) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
UA76085C2 (en) 2006-07-17
AP1374A (en) 2005-02-28
AU753014B2 (en) 2002-10-03
AU6039799A (en) 2000-04-03
HRP20010189A2 (en) 2005-04-30
PA8481901A1 (es) 2002-04-25
WO2000015262A1 (fr) 2000-03-23
PE20001061A1 (es) 2000-10-08
EA003476B1 (ru) 2003-06-26
OA11781A (en) 2005-07-26
NZ510168A (en) 2003-09-26
KR20010075063A (ko) 2001-08-09
BR9913722A (pt) 2001-05-29
JP2002524535A (ja) 2002-08-06
YU24201A (sh) 2003-08-29
HN1999000159A (es) 1999-11-11
CZ2001829A3 (cs) 2001-09-12
MY129282A (en) 2007-03-30
CA2343920A1 (fr) 2000-03-23
TR200101182T2 (tr) 2001-09-21
CO5130023A1 (es) 2002-02-27
LT2001021A (en) 2001-11-26
PL195574B1 (pl) 2007-10-31
HK1042231A1 (zh) 2002-08-09
EE200100151A (et) 2002-06-17
NO20011251D0 (no) 2001-03-13
LV12658B (lv) 2001-09-20
CN1317977A (zh) 2001-10-17
SK3442001A3 (en) 2001-11-06
IL141562A (en) 2007-07-24
BG105430A (en) 2001-12-29
PL346768A1 (en) 2002-02-25
NO20011251L (no) 2001-04-17
EA200100300A1 (ru) 2001-10-22
LT4897B (lt) 2002-02-25
EP1117442A1 (fr) 2001-07-25
ZA200101995B (en) 2002-03-11
SA99200718B1 (ar) 2006-11-04
UY25711A1 (es) 1999-11-17
LV12658A (lv) 2001-05-20
AP2001002093A0 (en) 2001-03-31
GEP20043257B (en) 2004-06-25
ID28845A (id) 2001-07-05
HUP0103837A3 (en) 2002-11-28
DZ2892A1 (fr) 2003-12-15
AR022090A1 (es) 2002-09-04
MA25590A1 (fr) 2002-12-31
IS5878A (is) 2001-03-05
IL141562A0 (en) 2002-03-10
HUP0103837A2 (hu) 2002-05-29
GT199900156A (es) 2001-03-07
TWI226248B (en) 2005-01-11

Similar Documents

Publication Publication Date Title
TNSN99173A1 (fr) Livraison d'agent actif sous forme de poudre seche
TNSN99188A1 (fr) Livraison d'agent actif atomise par modulation resistance de debit
Shinkar et al. Drug delivery from the oral cavity: A focus on mucoadhesive
Haberman et al. Contact dermatitis from beryllium in dental alloys
Sas et al. The intra-oral distribution of unstimulated and chewing-gum-stimulated parotid saliva
TNSN99038A1 (fr) Livraison d'un agent actif atomise
DE60326887D1 (de) Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
KR970705979A (ko) 치료용 매개체로서의 분무-건조 미소입자 (Spray-dried microparticles as therapeutic vehicles)
WO2001041707A3 (fr) Modulation in vivo des niveaux de glutamine et de glycine dans le traitement de l'autisme
BR9611815A (pt) Tablete de mascar com ação efervescente
NZ501950A (en) Medicinal compositions for application to mucosa
WO2008013929A3 (fr) Formulations anti-migraine en aérosol oral et procédés
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
EE04038B1 (et) Inhaleeritav formoterooli sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ning kasutamine
JP2004513093A5 (fr)
BRPI9910024B8 (pt) uso de uma mistura de alcoóis de açúcar contendo 6-o-alfa-d-glicopiranosil-d-sorbitol (1,6-gps) e 1-o-alfa-d-glicopiranosil-d-manitol (1,1-gpm) in vitro, e composição farmacêutica para consumo humano ou animal
AU9363398A (en) Hepatitis c receptor protein cd81
Purushotham et al. Absorption of epidermal growth factor occurs through the gastrointestinal tract and oral cavity in adult rats
EP1080225A4 (fr) Compositions et methodes d'administration aux poumons d'acides nucleiques
JPS5940137B2 (ja) 経口投与用医薬組成物
MXPA06007052A (es) Forma de dosificacion oral farmaceutica que comprende un farmaco anti-inflamatorio no esteroidal y que tiene buen sabor.
GB0018322D0 (en) Pharmaceutical compositions
CA2356306A1 (fr) Phosphatidylinositols sulfates, leur preparation et utilisation
Temple et al. The buccal absorption characteristics of fomocaine
Hochster et al. Cooperative Oncology Group Study (E1687)